<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00330018</url>
  </required_header>
  <id_info>
    <org_study_id>MYS-03-HMO-CTIL</org_study_id>
    <nct_id>NCT00330018</nct_id>
  </id_info>
  <brief_title>Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT)</brief_title>
  <official_title>An Investigator Initiated Prospective Randomized, Controlled Pilot Study in Order to Evaluate the Place of Valganciclovir in Prevention of Cytomegalovirus Reactivation Following Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rationale for this protocol is based on the need to assess if the current post stem cell&#xD;
      transplantation CMV prophylaxis strategies (e.g. high-dose acyclovir plus pre-emptive&#xD;
      treatment) can be improved by the use of valganciclovir. CMV is the most common viral&#xD;
      infection following stem cell transplantation, causing significant morbidity and mortality.&#xD;
      Furthermore, CMV has been shown to be associated with a number of indirect effects in SCT&#xD;
      recipients including allograft dysfunction, acute and chronic graft versus host disease&#xD;
      (GVHD). Valganciclovir is shown to be more active than oral ganciclovir, and as good as&#xD;
      intravenous (i.v.) ganciclovir in treating newly diagnosed CMV retinitis. The use of&#xD;
      valganciclovir for CMV prophylaxis post stem cell transplantation was never tested in&#xD;
      controlled study. The investigators therefore suggest a prospective, randomized study to&#xD;
      evaluate the efficacy and safety of valganciclovir compared with acyclovir for prevention of&#xD;
      CMV disease in allogeneic stem cell transplantation recipients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cytomegalovirus (CMV), the most common viral infection following stem cell transplantation&#xD;
      (SCT), causes significant morbidity and mortality. It can result in CMV pneumonitis,&#xD;
      hepatitis, encephalitis and gastrointestinal disease, as well as fever and neutropenia.&#xD;
      Furthermore, CMV has been shown to be associated with a number of indirect effects in SCT&#xD;
      recipients including reduced long-term patient survival, increased risks of opportunistic&#xD;
      infections, allograft dysfunction, acute and chronic graft vs. host disease (GVHD). SCT&#xD;
      patients at highest risk are seronegative donors, matched unrelated donors, SCT with T-cell&#xD;
      depletion, patients after cord blood SCT, and patients with GVHD.&#xD;
&#xD;
      Valganciclovir, a valine ester pro-drug of ganciclovir, was developed to overcome the&#xD;
      limitations of oral and i.v. ganciclovir, with a single once-daily 900 mg oral dose providing&#xD;
      comparable plasma ganciclovir exposures to those achieved with 5 mg/kg i.v. ganciclovir. Its&#xD;
      bioavailability is up to 10-fold higher than that of oral ganciclovir (same as above). There&#xD;
      is already extensive clinical experience with valganciclovir in AIDS patients, where it has&#xD;
      proved as effective as i.v. ganciclovir in treating newly diagnosed CMV retinitis, and in&#xD;
      patients after solid organ transplant but no comparative data exists in patients after SCT.&#xD;
&#xD;
      We therefore planned a prospective, randomized study to evaluate the efficacy and safety of&#xD;
      valganciclovir compared with acyclovir for prevention of CMV disease in SCT recipients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of CMV reactivation</measure>
    <time_frame>100d</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of CMV disease</measure>
    <time_frame>6m</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6m</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of GVHD</measure>
    <time_frame>6m</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of other infections</measure>
    <time_frame>6m</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bone Marrow Transplantation</condition>
  <condition>Cytomegalovirus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PO Valganciclovir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PO Acyclovir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir</intervention_name>
    <description>Valganciclovir</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyclovir</intervention_name>
    <description>Acyclovir</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Undergoing allogeneic SCT from a matched related or unrelated donor without T cell&#xD;
             depletion.&#xD;
&#xD;
          2. Had an acceptable engraftment.&#xD;
&#xD;
          3. Can take oral medications within 10 days of engraftment.&#xD;
&#xD;
          4. Either the recipient or donor (or both) is CMV seropositive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Not fulfilling the inclusion criteria.&#xD;
&#xD;
          2. History of CMV infection or disease.&#xD;
&#xD;
          3. Anti-CMV therapy within the past 15 days.&#xD;
&#xD;
          4. Severe, uncontrolled diarrhea.&#xD;
&#xD;
          5. Both recipient and donor are CMV seronegative.&#xD;
&#xD;
          6. Evidence of malabsorption.&#xD;
&#xD;
          7. Inability to comply with study requirements.&#xD;
&#xD;
          8. Known hypersensitivity or other contraindication to ganciclovir or valganciclovir.&#xD;
&#xD;
          9. Pregnant or lactating patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Y Shapira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Medical Organization,</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>May 24, 2006</study_first_submitted>
  <study_first_submitted_qc>May 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2006</study_first_posted>
  <last_update_submitted>April 19, 2015</last_update_submitted>
  <last_update_submitted_qc>April 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2015</last_update_posted>
  <responsible_party>
    <name_title>Michael Shapira, MD</name_title>
    <organization>Hadassah University Hospital</organization>
  </responsible_party>
  <keyword>BMT</keyword>
  <keyword>CMV</keyword>
  <keyword>GVHD</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

